| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | |
|---|---|---|---|---|
| Total other income (expense), net | -701 | -807 | -169 | |
| Income (loss) before provision for (benefit from) income taxes | -4,275 | 2,390 | -21,926 | |
| Provision for (benefit from) income taxes | 28 | 3 | -17 | |
| Net income (loss) | -4,303 | 2,387 | -21,909 | |
| Unrealized gain (loss) on available-for-sale securities | 2 | 0 | 36 | |
| Comprehensive income (loss) | -4,301 | 2,387 | -21,873 | |
| Earnings per share, basic | -0.32 | 0.2 | -2.93 | |
| Earnings per share, diluted | -0.32 | 0.19 | -2.93 | |
| Weighted average shares outstanding - basic | 13,564,000 | 12,197,000 | 7,466,000 | |
| Weighted average shares outstanding - diluted | 13,564,000 | 12,310,000 | 7,466,000 | |
Atara Biotherapeutics, Inc. (ATRA)
Atara Biotherapeutics, Inc. (ATRA)